NPPB and hydrops fetalis: While DEFINE-HF trial demonstrated, there was a meaningful improvement in Kansas City Cardiomyopathy Questionnaire overall summary score or NT-proBNP, 61.5% of dapagliflozin-treated patients versus 50.4% with placebo (adjusted OR 1.8, 95% CI 1.03–3.06, nominal P=0.039) [10].